Skip to main content
. 2016 Jun 22;107(8):1159–1164. doi: 10.1111/cas.12969

Figure 1.

Figure 1

Kaplan–Meier curves for progression‐free survival (PFS) (a) and overall survival (OS) (b) of WHO grade II–III tumors defined by IDH1/2 status. Survival was longer in IDH1/2 mutant cases than in IDH1/2 wild type cases for both PFS (median: IDH1/2 mutant, 63 months; IDH1 wild type, 12 months; P < 0.0001) and OS (median: IDH1/2 mutant, undefined; IDH1/2 wild type, 28 months; P < 0.0001). Even without 1p/19q‐codeleted (codel) tumors, which are known to have better prognosis, IDH1/2 mutant cases showed significantly longer survival than IDH1/2 wild type cases (PFS, median: IDH1/2 mutant, 51 months; IDH1/2 wild type, 12 months; P < 0.0001; OS, median: IDH1/2 mutant, undefined; IDH1/2 wild type, 28 months; P < 0.0001).